ClinicalTrials.gg
CompletedNCT06024265Updated Dec 19, 2025

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

An Early Phase 1 interventional study of ER2001 injection in Huntington Disease, sponsored by ExoRNA Bioscience. Completed at 1 site in China. Open to participants aged 25 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by ExoRNA Bioscience · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
25 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Huntington Disease with a site in China — 3 open to participants now, 4 under way, 1 of them phase 3. Huntington Disease · China.

Enrollment
10th of 12
10 · median 34
Started
2023
with 1 other
Phase 1
7 of 12
1 open now
Registered
4th of 12
by date
Lead sponsor
3 of 12
ExoRNA Bioscience

Among the 12 studies in Huntington Disease with a site in China, this one is the 10th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 4th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

3 of the 12 studies in Huntington Disease with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Huntington Disease with a site in China, or all of them as a file.
02

Study summary

This is an open label, dose escalation clinic trial of ER2001 intravenous injection to evaluate safety, tolerability and pharmacokinetics of ascending single and multiple doses of intravenously administered ER2001 in patients with early manifest Huntington's Disease. Furthermore, pharmacodynamics in particular target engagement, and early clinical signs of efficacy will be assessed. This study will evaluate increasing doses of ER2001 in sequential cohorts. ER2001 was escalated over 4 dose levels . The planned duration of this treatment is 14 weeks.

Read the detailed description

Participants will receive totally 8 intravenous injections of ER2001 on the first day of the study, after 2 weeks they will receive 6 injections at weekly intervals, followed by 1 injections at 6 weeks interval. The treatment period of 14 weeks will be followed by an observation phase of 84 days . A modified 3 plus 3 dose-escalation design will be employed with escalating rules set according to the incidence of dose-limiting toxicity (DLT). The first cohort of 1-6 participants will receive a low dose. After safety analysis the next cohort of 3-6 will received a higher dose. Planned doses for increase in subsequent cohorts are 0.04, 0.08, 0.16, and 0.32 mg/kg. Decision to proceed to the next higher dose cohort will be based upon a safety review of the included participants. Treatment will continue until intolerable toxicity or as per patient preference.

03

Conditions studied

  • Huntington Disease

Browse trials for

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has documented ability to understand the written study forms (ICFs) at the time of screening and has provided signed written informed consent prior to any study procedures.
  2. 25 Years to 55 Years. Gender is not limited.
  3. Early manifest HD as defined by a UHDRS total functional capacity (TFC) score of 9 to 13 and a diagnostic classification level (DCL) of 4.
  4. HTT gene expansion testing with the presence of ≥40 CAG repeats.
  5. Ability to undergo and tolerate MRI scans.
  6. Ability to undergo and tolerate lumbar puncture.
  7. All HD medications given for motor, behavioral, and cognitive symptoms have been stable for 3 months prior to Screening.
  8. Other concomitant medications have been stable for 1 month prior to Screening.
  9. organ function measured prior to administration of study treatment.
  10. or evidence of non-childbearing status for women of . Male patients must use a condom during treatment and for 6 months after the last dose of ER2001 when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of if they are of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  1. History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening.
  2. Current active psychosis, confusional state, or violent behavior.
  3. Bleeding tendency or history of coagulation disorder; As long as the investigator confirms that there is no evidence of bleeding tendency or coagulation dysfunction at present.
  4. with interval (QTc) > 480 ms and/or indication of uncontrolled cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction,congestive heart failure, electrolyte disturbances, etc.)
  5. Patients with , Treponema pallidum, , or infection.
  6. Need to take antiretroviral drugs, including antiretroviral drugs as preventive treatment.
  7. Current or recurrent disease, infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a subject's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule.
  8. Clinical diagnosis of chronic migraines.
  9. Presence of an implanted deep brain stimulation device, ventriculoperitoneal or other CSF shunt, or other implanted catheter.
  10. Preexisting structural brain lesions (such as tumor, arteriovenous malformation) as assessed by a centrally read MRI scan during the screening period.
  11. Any history of gene therapy, RNA or DNA agents, such as antisense oligonucleotides (ASO), cell transplantation or any other experimental brain surgery.
  12. Treatment with investigational therapy within 4 weeks prior to screening or 5 drug elimination half-lives of investigational therapy, whichever is longer.
  13. Unable or unsafe to perform lumbar puncture on the patient.
  14. In the Investigator's judgment, that Parkinson's disease, multiple system atrophy and other dystonia diseases may be combined.
  15. Patients who are hypersensitive to any ingredients in the formulation of ER2001.
  16. within 5 years of screening, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
  17. Concurrent or planned concurrent participation in any interventional clinical study, including explicit pharmacological and non-pharmacological interventions. Observational studies are acceptable.
  18. Any serious medical condition or laboratory, vital signs, or abnormalities at screening that, in the Investigator's judgment, precludes the patient's safe participation in and completion of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ER2001 Injection

    The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.

    Drug: ER2001 injection

Interventions

  • The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.

    Also known as: ER2001 intravenous injection solution

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of adverse events (AEs) and serious adverse events (SAEs)

    To evaluate the safety and tolerability of ER2001 injection.

    Time frame: Approximately 6.5 months

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    To assess the Pharmacokinetics (PK) of ER2001 injection.

    Time frame: Approximately 3.5 months

  2. Terminal half-life (t1/2)

    To assess the Pharmacokinetics (PK) of ER2001 injection.

    Time frame: Approximately 3.5 months

  3. Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration (AUC0-t)

    To assess the Pharmacokinetics (PK) of ER2001 injection.

    Time frame: Approximately 3.5 months

  4. Maximum concentration (Cmax) in cerebrospinal fluid (CSF)

    To assess the Pharmacokinetics (PK) of ER2001 injection.

    Time frame: Approximately 3.5 months

Other outcomes

  1. Immunogenicity

    To collect the incidence of Anti-Drug Antibodies (ADAs).

    Time frame: approximately- 6.5 months

  2. Change from baseline in the concentration of mutant huntingtin (mHTT) protein in cerebrospinal fluid (CSF)

    To assess the dose-response relationship of ER2001 injection on mHTT protein change from baseline in cerebrospinal fluid (CSF).

    Time frame: approximately- 6.5 months

  3. Change from baseline in Unified Huntington's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC) score

    UHDRS is a research tool developed by Huntington Disease (HD) Study Group to provide a uniform assessment of the clinical features and course of HD. The UHDRS TFC comprises 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.

    Time frame: approximately- 6.5 months

  4. Change from baseline in Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score (TMS) score

    UHDRS is a research tool developed by Huntington Disease (HD) Study Group to provide a uniform assessment of the clinical features and course of HD. The UHDRS TMS assesses all the motor features of HD and includes maximal chorea, maximal dystonia, ocular pursuit, saccade initiation and velocity, dysarthria, tongue protrusion, finger tapping, hand pronation and supination, luria, rigidity, bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these was rated on a scale of 0 (normal motor function) to 4 (severely impaired motor function). TMS score is a sum of individual scores ranging from 0 (normal motor function) to 124 (severely impaired motor function). Lower TMS scores indicate better motor function.

    Time frame: approximately- 6.5 months

07

Study locations

1 site
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510080, China
08

References and documents

Publications

  • Zhang L, Wu T, Shan Y, Li G, Ni X, Chen X, Hu X, Lin L, Li Y, Guan Y, Gao J, Chen D, Zhang Y, Pei Z, Chen X. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs. Brain. 2021 Dec 16;144(11):3421-3435. doi: 10.1093/brain/awab354. PubMed 34918046 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jan 2025, 21 months.

Of 19 phase 1 interventional studies under Huntington Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Sep 6, 2023
StartActual
Apr 4, 2023
Primary completionActual
Jan 31, 2025
CompletionActual
Sep 4, 2025
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06024265
Lead sponsor
ExoRNA Bioscience
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Apr 4, 2023
Primary completion
Jan 31, 2025
Completion
Sep 4, 2025
Last update
Dec 19, 2025

Study contacts

Xia Meng, Ph.D
study chair · ExoRNA Bioscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ER2001

Start the discussion